Molecular mechanisms of prolactin and its receptor

Endocrine Reviews

Volumn 33, Issue 4, 2012, Pages 504-525

  Brooks, Charles L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYSTEINE; DISULFIDE; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; JANUS KINASE 2; PEPTIDYLPROLYL ISOMERASE; PLACENTA LACTOGEN; PROLACTIN; PROLACTIN RECEPTOR; PROLINE; PROTEIN SH2; ZINC ION;

ACETYLATION; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; HUMAN; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STOICHIOMETRY; THERMODYNAMICS;

AMINO ACID SEQUENCE; ANIMALS; ERYTHROPOIETIN; GROWTH HORMONE; HUMANS; MOLECULAR STRUCTURE; PROLACTIN; PROTEIN ISOFORMS; RECEPTORS, PROLACTIN; THERMODYNAMICS;

EID: 84865984323     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2011-1040     Document Type: Article

References (162)

1. Huising MO, Kruiswijk CP, Flik G. 2006 Phylogeny and evolution of class-1 helical cytokines. J Endocrinol 189: 1-25
2. Forsyth IA, Wallis M. 2002 Growth hormone and prolactin- molecular and functional evolution. J Mammary Gland Biol Neoplasia 7:291-312
3. Wallis OC, Mac-Kwashie AO, Makri G, Wallis M. 2005 Molecular evolution of prolactin in primates. J Mol Evol 60:606-614
4. Kelly PA, Djiane J, Postal-Vinay MC, Edery M. 1991 The prolactin/growth hormone receptor family. Endocr Rev 12:235-251
5. Clevenger CV, Kline JB. 2001 Prolactin receptor signal transduction. Lupus 10:706-718
6. Watson CJ, BurdonTG. 1996 Prolactin signal transduction mechanisms in themammarygland: The role of the Jak/Stat pathway. Rev Reprod 1:1-5
7. Nicoll CS. 1974 Physiological actions of prolactin. In: Knobil E, Sawyer WH, eds. Handbook of physiology. Section
8. Endocrinology. Washington, DC: American Physiological Society; 253-292
9. Bernichtein S, Touraine P, Goffin V. 2010 New concepts in prolactin biology. J Endocrinol 206:1-11
10. Grattan DR, Kokay IC. 2008 A pleiotropic neuroendocrine hormone. J Neuroendocrinol 20:752-763
11. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. 2003 The role of prolactin in mammary carcinoma. Endocr Rev 24:1-27
12. Ben-Jonathan N, Liby K, McFarland M, Zinger M. 2002 Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 13:245-250
13. Goffin V, Bernichtein S, Touraine P, Kelly PA. 2005 Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 26:400-422
14. Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N. 2010 Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol Metab 21:691-698
15. Kossiakoff AA, Clevenger CV. 2010 Growth hormone and prolactin family of hormone receptors: the structural basis of receptor activation and regulation. In: Bradshaw RA, Dennis EA, eds. Handbook of cellular signaling. 2nd ed. Vol 3. Chap 36. Amsterdam: Elsevier; 237-243
16. Teilum K, Hoch JC, Goffin V, Kinet S, Martial JA, KragelundBB. 2005 Solution structure of human prolactin. J Mol Biol 351:810-823
17. Jomain JB, Tallet E, Broutin I, Hoos S, van Agthoven J, Ducruix A, Kelly PA, Kragelund BB, England P, Goffin V. 2007 Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: x-ray structure of Del1-9-G129R-hPRL. J Biol Chem 282:33118-33131
18. Svensson LA, Bondensgaard K, Nørskov-Lauritsen L, Christensen L, Becker P, Andersen MD, Maltesen MJ, Rand KD, Breinholt J. 2008 Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor. J Biol Chem 283:19085-19094
19. Broutin I, Jomain JB, Tallet E, van Agthoven J, Raynal B, Hoos S, Kragelund BB, Kelly PA, Ducruix A, England P, Goffin V. 2010 Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2. J Biol Chem 285: 8422-8433
20. Kulkarni MV, Tettamanzi MC, Murphy JW, Keeler C, Myszka DG, Chayen NE, Lolis EJ, Hodsdon ME. 2010 Two independent histidines, one in human prolactin and one in its receptor, are critical for pH-dependent receptor recognition and activation. J Biol Chem 285:38524- 38533
21. van Agthoven J, Zhang C, Tallet E, Raynal B, Hoos S, Baron B, England P, Goffin V, Broutin I. 2010 Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone. J Mol Biol 404:112-126
22. Somers W, Ultsch M, De Vos AM, Kossiakoff AA. 1994 The x-ray structure of a growth hormone-prolactin receptor complex. Nature 372:478-481
23. Walsh ST, Kossiakoff AA. 2006 Crystal structure and site 1 binding energetics of human placental lactogen. J Mol Biol 358:773-784
24. Kamtekar S, HechtMH. 1995 The four helix bundle: what determines a fold? FASEB J 9:1013-1022
25. Chaiken IM, Williams WV. 1996 Identifying structurefunction relationships in four-helix bundle cytokines: towards de novo mimetics design. Trends Biotechnol 14: 369-375
26. Elkins PA, Christinger HW, Sandowski Y, Sakal E, Gertler A, de Vos AM, Kossiakoff AA. 2000 Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor. Nat Struct Biol 7:808-815
27. Hooper KP, Padmanabhan R, Ebner KE. 1993 Expression of the extracellular domain of the rat prolactin receptor and its interaction with ovine prolactin. J Biol Chem 268: 22347-22352
28. Sivaprasad U, Canfield JM, Brooks CL. 2004 Mechanism for ordered receptor binding by human prolactin. Biochemistry 43:13755-13765
29. Voorhees JL, Brooks CL. 2010 Obligate ordered binding of human lactogenic cytokines. J Biol Chem 285:20022- 20030
30. Rao GV, Brooks CL. 2011 Functional epitopes for site 1 of human prolactin. Biochemistry 50:1347-1358
31. DePristo MA, de Bakker PI, Blundell TL. 2004 Heterogeneity and inaccuracy in protein structures solved by x-ray crystallography. Structure 12:831-838
32. Bernichtein S, Jomain JB, Kelly PA, Goffin V. 2003 The N-terminus of human prolactin modulates its biological properties. Mol Cell Endocrinol 208:11-21
33. Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA, Goffin V. 2003 Development of pure prolactin receptor antagonists. J Biol Chem 278:35988-35999
34. Doneen BA, Bewley TA, Li CH. 1979 Studies on prolactin. Selective reduction of the disulfide bonds of ovine hormone. Biochemistry 18:4851-4860
35. Schleyer M, Etzrodt H, Trah TJ, Voigt KH. 1982 Dependence of human somatotropin activity on interchain disulfide bridges. Hoppe Seylers Z Physiol Chem 363:1111- 1116
36. Handwerger S, Pang EC, Aloj SM, Sherwood LM. 1972 Correlations in the structure and function of human placental lactogen and human growth hormone. I. Modification of the disulfide bonds. Endocrinology 91:721-727
37. Kim BG, Brooks CL. 1993 Isolation and characterization of phosphorylated bovine prolactin. Biochem J 296:41-47
38. Dattani MT, Hindmarsh PC, Brook CG, Robinson IC, Kopchick JJ, Marshall NJ. 1995 G120R, a human growth hormone antagonist, shows zinc-dependent agonist and antagonist activity on Nb2 cells. J Biol Chem 270:9222- 9226
39. ChenWY,Chen NY, Yun J, Wagner TE, Kopchick JJ. 1994 In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem 269:15892-15897
40. Duda KM, Brooks CL. 2003 Identification of residues outside of the two binding sites that are critical for activation of the lactogenic activity of human growth hormone. J Biol Chem 278:22734-22739
41. PaulingL. 1935 The oxygen equilibrium of hemoglobin and its structural interpretation. Proc Natl Acad Sci USA 21: 186-191
42. Wyman Jr J. 1948 Heme proteins. Adv Protein Chem 4:407-531
43. Wyman J, Gill SJ. 1990 Binding and linkage. Mill Valley, CA: University Science Books
44. Mondo J, Wyman J, Changeux JP. 1965 On the nature of allosteric transitions: a plausible model. J Mol Biol 12:88- 118
45. Koshland Jr DE, Némethy G, Filmer D. 1966 Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5:365-385
46. Tsai CJ, del Sol A, Nussinov R. 2008 Allostery: absence of a change in shape does not imply that allostery is not at play. J Mol Biol 378:1-11
47. Clore GM. 2011 Exploring sparsely populated states of macromolecules by dimagnetic and paramagnetic NMR relaxation. Prot Sci 20:229-246
48. Laskowski RA, Gerick F, Thornton JM. 2009 The structural basis of allosteric regulation in proteins. FEBS Lett 583:1692-1698
49. Lakowicz JR. 2006 Principles of fluorescence spectroscopy. 3rd ed. New York: Springer
50. Wrabl JO, Gu J, Liu T, Schrank TP, Whitten ST, Hilser VJ. 2011 The Role of protein conformational fluctuations in allostery, function, and evolution. Biophys Chem 159: 129-141
51. di Cera E. 1998 Site-specific analysis of mutational effects in proteins. Adv Protein Chem 51:59-119
52. Walsh ST, Sylvester JE, KossiakoffAA. 2004 The high- and low-affinity receptor binding sites of growth hormone are allosterically coupled. Proc Natl Acad Sci USA 101: 17078-17083
53. Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME. 2007 The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologicalpHrange. Biochemistry 46:2398-2410
54. Tettamanzi MC, Keeler C, Meshack S, HodsdonME. 2008 Analysis of site-specific histidine protonation in human prolactin. Biochemistry 47:8638-8647
55. Behncken SN, Rowlinson SW, Rowland JE, Conway-Campbell BL, Monks TA, Waters MJ. 1997 Engineering porcine growth hormone to activate the human receptor. J Biol Chem 272:27077-27083
56. Peterson FC, Brooks CL. 2000 The species specificity of growth hormone requires the cooperative interaction of two motifs. FEBS Lett 472:276-282
57. ++. Mol Endocrinol 10:265-271
58. 2+-binding properties of bovine prolactin. FEBS Lett 405:273-276
59. Voorhees JL, Rao GV, Gordon TJ, Brooks CL. 2011 Zinc binding to human lactogenic hormones and the human prolactin receptor. FEBS Lett 585:1783-1788
60. Burtis CA, Ashwood ER. 2001 Teitz fundamentals of clinical chemistry. 5th ed. Philadelphia: Saunders
61. 2+ in equine plasma blood. J Biol Chem 262:11140-11148
62. LowmanHB, Cunningham BC, Wells JA. 1991 Mutational analysis and protein engineering of receptor binding determinates of human placental lactogen. J Biol Chem 266: 10982-10988
63. Greenan J, Lorenson MY, Conconi MV, WalkerAM. 1990 Alterations in in situ prolactin secretory granule morphology and immunoactivity by thiols and divalent cations. Endocrinology 126:512-518
64. 2+. Mol Endocrinol 11:1544-1551
65. Brooks CL, Welsch CW. 1978 Effects of the association time of in vivo bound prolactin on the [125I] prolactin receptor assays of female rat livers. Mol Cell Endocrinol 11: 145-151
66. Joss L, Morton TA, Doyle ML, Myszka DG. 1998 Interpreting kinetic rate constants from optical biosensor data recorded on a decaying surface. Anal Biochem 261:203- 210
67. Gertler A, Grosclaude J, Strasburger CJ, Nir S, Djiane J. 1996 Real-time kinetic measurements of the interaction between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization. J Biol Chem 271:24482-24491
68. Cunningham BC, Wells JA. 1993 Comparison of a structural and a functional epitope. J Mol Biol 234:554-563
69. Walsh ST, Jevitts LM, Sylvester JE, Kossiakoff AA. 2003 Site 2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization. Protein Sci 12:1960-1970
70. Rui H, Kirken RA, FarrarWL. 1994 Activation of receptorassociated tyrosine kinase JAK2 by prolactin. J Biol Chem 269:5364-5368
71. Tan D, Huang KT, Ueda E, WalkerAM. 2008 S2 Deletion variants of human PRL receptors demonstrate that extracellular domain can alter conformation of the intracellular signaling domain. Biochemistry 47:479-489
72. Lee RC, Walters JA, Reyland ME, Anderson SM. 1999 Constitutive activation of the prolactin receptor results in the induction of growth factor-independent proliferation and constitutive activation of signaling molecules. J Biol Chem 274:10024-10034
73. Gourdou I, Gabou L, Paly J, Kermabon AY, Belair L, Djiane J. 1996 Development of a constitutively active mutant form of the prolactin receptor, a member of the cytokine receptor family. Mol Endocrinol 10:45-56
74. Gadd SL, Clevenger CV. 2006 Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol 20:2734-2746
75. Qazi AM, Tsai-Morris CH, Dufau ML. 2006 Ligandindependent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Mol Endocrinol 20:1912- 1923
76. Liu W, Brooks CL. 2011 Functional impact of manipulation on the relative orientation ofhumanprolactin receptor domains. Biochemistry 50:5333-5344
77. Tan D, Johnson DA,WuW, Zeng L, Chen YH, Chen WY, Vonderhaar BK, Walker AM. 2005 Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short human PRL receptors in living human cells. Mol Endocrinol 19:1291-1303
78. Ilondo MM, Damholt AB, Cunningham BA, Wells JA, De Meyts P, Shymko RM. 1994 Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. Endocrinology 134:2397-2403
79. Goffin V, Kinet S, Ferrag F, Binart N, Martial JA, Kelly PA. 1996 Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J Biol Chem 271:16573-16579
80. Duda KM, Brooks CL. 1999 Human growth hormone site 2 lactogenic activity requires a distant tyrosine 164. FEBS Lett 449:120-124
81. Boutin JM, Edery M, Shirota M, Jolicoeur C, Lesueur L, Ali S, Gould D, Djiane J, Kelly PA. 1989 Identification of a cDNA encoding a long form of prolactin receptors in human hepatoma and breast cancer cells. Mol Endocrinol 3:1455-1461
82. Kline JB, Roehrs H, Clevenger CV. 1999 Functional characterization of intermediate isoforms of the human prolactin receptor. J Biol Chem 274:35461-35468
83. Hu ZZ, Meng J, Dufau ML. 2001 Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon J Biol Chem 276:41086-41094
84. Kline JB, Rycyzyn MA, Clevenger CV. 2002 Characterization of a novel and functional human prolactin receptor isoform (ΔS1PRLr) containing only one extracellular fibronectin-like domain. Mol Endocrinol 16:2310-2322
85. Trott JF, Hovey RC, Koduri S, Vonderhaar BK. 2003 Alternative splicing of exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. J Mol Endocrinol 30:31-47
86. Kline JB, Clevenger CV. 2001 Identification and characterization of the prolactin-binding protein (PRLBP) in human serum and milk. J Biol Chem 276:24760-24766
87. Binart N, Bachelot A, Bouilly J. 2010 Impact of prolactin receptor isoforms on reproduction. Trends Endocrinol Metab 21:362-368
88. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P. 2008 Identification of a gainof-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci USA 105: 14533-14538
89. Goffin V, Bogorad RL, Touraine P. 2010 Identification of gain-of-function variants of the human prolactin receptor. Methods Enzymol 484:329-355
90. Urbanek M, Russell JE, Cooke NE, Liebhaber SA. 1993 Functional characterization of the alternatively spliced placental human growth hormone receptor. J Biol Chem 268: 19025-19032
91. Dastot F, Sobrier ML, Duquesnoy P, Duriez B, Goossens M, Amselem S. 1996 Alternatively spliced forms in the cytoplasmic domain of the human growth (GH) receptor regulate its ability to generate a soluble GH-binding protein. Proc Natl Acad Sci USA 93:10723-10728
92. Ross RJ, Esposito N, Shen XY, Von Laue S, Chew SL, Dobson PR, Postel-Vinay MC, Finidori J. 1997 A short isoform of the human growth hormone receptor functions as a dominate negative inhibitor of the full length receptor and generates large amounts of binding protein. Mol Endocrinol 11:265-273
93. Amit T, Bergman T, Dastot F, Youdim MB, Amselem S, Hochberg Z. 1997 A membrane-fixed, truncated form of the human growth hormone receptor. J Clin Endocrinol Metab 82:3813-3817
94. Ayling RM, Ross R, Towner P, Von Laue S, Finidori J, Moutoussamy S, Buchanan CR, Clayton PE, NormanMR. 1997 A dominate negative mutation of the growth hormone receptor causes familial short stature. Nat Genet 16: 13-14
95. Arcasoy MO, Jiang X, Haroon ZA. 2003 Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Comm 307:999-1007
96. Bazan JF. 1990 Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad SciUSA 87:6934-6938
97. Rozakis-Adcock M, Kelly PA. 1991 Mutational analysis of the ligand-binding domain of the prolactin receptor. J Biol Chem 266:16472-16477
98. Xie YL, Hassan SA, QaziAM,Tsai-Morris CH, DufauML. 2009 Intramolecular disulfide bonds of the prolactin receptor short form are required for its inhibitory action on the function of the long form of the receptor. Mol Cell Biol 29:2546-2555
99. Frank SJ, Gilliland G, Van EppsC. 1994 Treatment of IM-9 cells with human growth hormone (GH) promotes rapid disulfide linkage ofGHreceptor. Endocrinology 135:148- 156
100. Zhang Y, Jiang J, Kopchick JJ, Frank SJ. 1999 Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-inducedGHRdimerization. Association of JAK2 with GHR is enhanced by dimerization. J Biol Chem 274: 33072-33084
101. Yang N, Langenheim JF, Wang X, Jiang J, Chen WY, Frank SJ. 2008 Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering. Mol Endocrinol 22:978- 988
102. Miura O, Ihle JN. 1993 Dimer- and oligomerization of the erythropoietin receptor by disulfide bond formation and significance of the region near the WSXWS motif in intracellular transport. Arch Biochem Biophys 306:200-208
103. Rozakis-Adcock M, Kelly PA. 1992 Identification of ligand binding determinates of the prolactin receptor. J BiolChem 267:7428-7433
104. de Vos AM, Ultsch M, Kossiakoff AA. 1992 Human growth hormone and the extracellular domain of its receptor: crystal structure of the complex. Science 255:306- 312
105. Mitani M, Dufau ML. 1986 Purification and characterization of prolactin receptors from the ovary. J Biol Chem 261:1309-1315
106. Okamura H, Raguet S, Bell A, Gagnon J, Kelly PA. 1989 Purification and protein sequence analysis of rat liver prolactin receptor. J Biol Chem 264:5904-5911
107. Buteau H, Pezet A, Ferrag F, Perrot-Applanat M, Kelly PA, EderyM. 1998 N-Glycosylation of the prolactin receptor is not required for activation of gene transcription but is critical for its cell surface targeting. Mol Endocrinol 12:544- 555
108. ChangWP,YeY, ClevengerCV. 1998 Stoichiometric structure-function analysis of prolactin receptor signaling domain by receptor chimeras. Mol Cell Biol 18:896-905
109. Landschulz WH, Johnson PF, McKnight SL. 1988 The leucine zipper: a hypothetical structurecommonto anewclass of DNA binding proteins. Science 240:1759-1764
110. Miller M. 2009 The importance of being flexible: the case of basic region leucine zipper transcription regulators. Curr Protein Pept Sci 10:244-269
111. Ryadnov MG, Papapostolou D, Woolfson DN. 2008 The leucine zipper as a building block for self-assembled protein fibers. Methods Mol Biol 474:35-51
112. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ. 2005 Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 12:814-821
113. Ruan W, Becker V, Klingmüller U, Langosch D. 2004 The interface between self-assembling erythropoietin receptor transmembrane segments corresponds to a membranespanning leucine zipper. J Biol Chem 279:3273-3279
114. Kubatzky KF, Ruan W, Gurezka R, Cohen J, Ketteler R, Watowich SS, Neumann D, Langosch D, Klingmüller U. 2001 Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol 11:110-115
115. Yang N, Wang X, Jiang J, Frank SJ. 2007 Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Mol Endocrinol 21:1642-1655
116. Uversky VN, Gillespie JR, Fink AL. 2000 Why are "natively unfolded"proteins unstructured under physiological conditions? Proteins 41:415-427
117. Ren S, Uversky VN, Chen Z, Dunker AK, Obradovic Z. 2008 Short linear motifs recognized by SH2, SH3 and Ser/ Thr kinase domains are conserved in disordered protein regions. BMC Genomics 9(Suppl 2):S26
118. Rost B. 1996 PHD: predicting one-dimensional protein structure by profile-based neural networks. Methods Enzymol 266:525-539
119. Rost B, Yachdav G, Liu J. 2004 The ProteinPredict server. Nucleic Acids Res 32:W321-W326
120. Goujon L, Allevato G, Simonin G, Paquereau L, LeCamA, Clark J, Nielsen JH, Djiane J, Postel-Vinay MC, Edery M. 1994 Cytoplasmic sequences of the growth hormone receptor necessary for signal transduction. Proc Natl Acad Sci USA 91:957-961
121. Venkitaraman AR, Cowling RJ. 1992 Interleukin 7 receptor functions by recruiting the tyrosine kinase p59fyn through a segment of its cytoplasmic tail. Proc Natl Acad Sci USA 89:12083-12087
122. Pezet A, Buteau H, Kelly PA, EderyM. 1997 The last proline of box 1 is essential for association with JAK2 and the functional activation of the prolactin receptor. Mol Cell Endocrinol 129:199-208
123. O'Neal KD, Chari MV, Mcdonald CH, Cook RG, Yu-Lee LY, Morrisett JD, Shearer WT. 1996 Multiple cis-transconformers of the prolactin receptor proline-rich motif (PRM) peptide detected by reverse-phase HPLC, CD and NMR spectroscopy. Biochem J 315:833-844
124. Lu KP, Finn G, Lee TH, Nicholson LK. 2007 Prolyl cistrans isomerization as a molecular timer. Nat Chem Biol 3:619-629
125. Campbell GS, Argetsinger LS, Ihle JN, Kelly PA, Rillema JA, Carter-Su C. 1994 Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants. Proc Natl Acad Sci USA 91:5232-5236
126. Clevenger CV, Medaglia MV. 1994 The protein tyrosine kinase p59fyn is associated with the prolactin (PRL) receptor and is activated by prolactin stimulation of T-lymphocytes. Mol Endocrinol 8:674-681
127. Clevenger CV, Torigoe T, Reed JC. 1994 Prolactin induces rapid phosphorylation and activation of prolactin receptor associated Raf-1 kinase in a T-cell line. J Biol Chem 269: 5559-5565
128. Clevenger CV, Ngo W, Sokol DL, Luger SM, GewirtzAM. 1995 VAV is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. J Biol Chem 270:13246-13253
129. Schlessinger J, Lemmon MA. 2003 SH2 and PTB domains in tyrosine kinase signaling. Sci STKE 2003:RE12
130. Liu BA, Jablonowski K, Raina M, Arcé M, Pawson T, Nash PD. 2006 The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. Mol Cell 22:851-868
131. Pezet A, Ferrag F, Kelly PA, EderyM. 1997 Tyrosine docking sites of the rat prolactin receptor required for association and activation of STAT5. J Biol Chem 272:25043- 25050
132. Lebrun JJ, Ali S, Goffin V, Ullrich A, Kelly PA. 1995 A single phosphotyrosine residue of the prolactin receptor is responsible for activation of gene transcription. Proc Natl Acad Sci USA 92:4031-4035
133. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V, SullivanM. 2012 PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in men and mouse. Nucleic Acids Res 40:D261-D270
134. Choudhary C, Mann M. 2010 Decoding signalling networks by mass spectrometry-based proteomics. Nat Rev Mol Cell Biol 11:427-439
135. Kosako H, Nagano K. 2011 Quantitative phosphoproteomics strategies for understanding protein kinase-mediated signaling transduction pathways. Expert Rev Proteomics 8:81-94
136. Olayioye MA, Guthridge MA, Stomski FC, Lopez AF, Visvader JE, Lindeman GJ. 2003 Threonine 391 phosphorylation of human prolactin receptor mediates a novel interaction with 14-3-3 proteins. J Biol Chem 278:32929-32935
137. Ma L, Gao JS, Guan Y, Shi X, Zhang H, Ayrapetov MK, Zhang Z, Xu L, Hyun YM, Kim M, Zhuang S, Chin YE. 2010 Acetylation modulates prolactin receptor dimerization. Proc Natl Acad Sci USA 107:19314-19319
138. Aitken A. 2006 14-3-3 proteins: a historic overview. Semin Cancer Biol 16:162-172
139. McManus KJ, Hendzel MJ. 2001 CBP, a transcriptional coactivator and acetyltransferase. Biochem Cell Biol 79: 253-266
140. Goffin V, Kelly PA. 1997 The prolactin/growth hormone receptor family: structure/function relationships. J Mammary Gland Biol Neoplasia 2:7-17
141. Kossiakoff AA, Somers W, Ultsch M, Andow K, Muller YA, De Vos AM. 1994 Comparison of the intermediate complexes ofhumangrowth hormone bound to thehuman growth and prolactin receptors. Protein Sci 3:1697-1705
142. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. 1991 Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254:821-825
143. Kossiakoff AA. 2004 The structural basis for biological signaling, regulation, and specificity in the growth hormone/ prolactin system of hormones and receptors. Adv Protein Chem 68:147-169
144. Langenheim JF, Tan D, Walker AM, ChenWY. 2006 Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. Mol Endocrinol 20:661-674
145. Rui H, Lebrun JJ, Kirken RA, Kelly PA, Farrar WL. 1994 JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology 135:1299-1306
146. Djiane J, Houdebine LM, Kelly PA. 1981 Prolactin-like activity of anti-prolactin receptor antibodies on casein and DNA synthesis in the mammary gland. Proc Natl Acad Sci USA 78:7445-7448
147. Dusanter-Fourt I, Muller O, Ziemiecki A, Mayeux P, Drucker B, Djiane J, Wilks A, Harpur AG, Fischer S, Gisselbrecht S. 1994 Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells. EMBO J 13:2583-2591
148. Cunningham BC, Wells JA. 1989 High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244:1081-1085
149. Clevenger CV, Gadd SL, Zheng J. 2009 New mechanism for PRL action in breast cancer. Trends Endocrinol Metab 20:223-229
150. Walker AM. 2007 S179D prolactin: antagonistic agony. Mol Cell Endocrinol 276:1-9
151. Varghese B, Barriere H, Carbone CJ, Banerjee A, Swaminathan G, Plotnikov A, Xu P, Peng J, Goffin V, Lukacs GL, Fuchs SY. 2008 Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway. Mol Cell Biol 28:5275-5287
152. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. 1999 Crystallographic evidence for performed dimers of erythropoietin receptor before ligand activation. Science 283:987-990
153. Remy I, Wilson IA, Michnick SW. 1999 Erythropoietin receptor activation by a ligand-induced conformation change. Science 283:990-993
154. Watowich SS. 1999 Activation of erythropoietin signaling by receptor dimerization. Int J Biochem Cell Biol 31:1075- 1088
155. Watowich SS, Yoshimura A, Longmore GD, Hilton DJ,Yoshimura Y, Lodish HF. 1992 Homodimerization and constitutive activation of the erythropoietin receptor. Proc Natl Acad Sci USA 89:2140-2144
156. Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ. 2006 New insights into growth hormone action. J Mol Endocrinol 36:1-7
157. Constantinescu SN, Huang LJ, Nam H, Lodish HF. 2001 The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 7:377-385
158. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, StroudRM. 1998 Efficiency of signaling through cytokine receptors depends critically on receptor orientation. Nature 395:511-516
159. Ellgaard L, Ruddock LW. 2005 The human protein disulfide isomerase family: Substrate interactions and functional properties. EMBO Rep 6:28-32
160. Syed F, Rycyzyn MA, Westgate L, Clevenger CV. 2003 A novel and functional interaction between cyclophilin A and prolactin receptor. Endocrine 20:83-90
161. Zheng J, Koblinski JE, Dutson LV, Feency YB, Clevenger CV. 2008 Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression ofhumanbreast cancer. Cancer Res 68:7769-7778
162. Tang X, Gao JS, Guan YJ, McLane KE, Yuan ZL, Ramratnam B, Chin YE. 2007 Acetylation-dependent signal transduction for type 1 interferon receptor. Cell 131:93-105